BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tiotropium bromide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tiotropium bromide\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06679465-3525@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tiotropium bromide: Phase 4 readout est. (NCT06679465)
DESCRIPTION:Tiotropium bromide\, phase 4\, Asthma.\nStudy: Evaluating the I
 mpact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Respon
 se\nEstimated primary completion: January 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tiotropium-bromide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06679465
URL:https://assetmemo.bio/drug/tiotropium-bromide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827859-3525@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Tiotropium bromide: Phase 4 readout est. (NCT07827859)
DESCRIPTION:Tiotropium bromide\, phase 4.\nStudy: PREterm Infants With Bron
 chial Obstruction - Prospective Study of Efficacy and Safety of Inhaled Ti
 otropium\nEstimated primary completion: 1 May 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tiotropium-bromide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07827859
URL:https://assetmemo.bio/drug/tiotropium-bromide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
